ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2016
Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- A potential fate decision landscape of the TWEAK/Fn14 axis on stem and progenitor cells: a systematic review.Stem cell research & therapy · 2022Pooled it
- Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Renal failure · 2021Pooled it
- Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2019Pooled it
- Serum CXCL10 as a potential biomarker for lupus nephritis and disease activity: evidence from an Egyptian cohort.BMC nephrology · 2026Article
- The TWEAK-HOIP-HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation.Mediators of inflammation · 2026Article
- Urinary TWEAK reflects disease activity in ANCA-associated vasculitis.Clinical kidney journal · 2025Article
- Decreased Aortic Elasticity in Rheumatoid Arthritis: An Early Sign of Atherosclerosis and Predictive Factors.European journal of rheumatology · 2024Article
- Lupus Nephritis Biomarkers: A Critical Review.International journal of molecular sciences · 2024Review
- Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.Journal of clinical medicine · 2022Review
- Dysfunction of CD27Clinical rheumatology · 2022Article
- Diagnostic test accuracy of novel biomarkers for lupus nephritis-An overview of systematic reviews.PloS one · 2022Review
- Article
- TWEAK/Fn14 Activation Participates in Skin Inflammation.Mediators of inflammation · 2017Review
- Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay.Clinical proteomics · 2017Article
- TWEAK/Fn14 Activation Participates in Ro52-Mediated Photosensitization in Cutaneous Lupus Erythematosus.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to identify serum and urine biomarkers that correlate with disease activity in female patients with systemic lupus erythematosus (SLE).
methodsSerum and urine levels of interferon γ-induced protein-10 (IP-10), TNF-like weak inducer of apoptosis (TWEAK), and monocyte chemotactic protein-1 (MCP-1) of 70 patients with SLE and 61 healthy controls were measured with enzyme-linked immunosorbent assays.
resultsThe serum and urine levels of TWEAK, IP-10, and MCP-1 in both high and low SLE disease activity index (SLEDAI) groups of SLE patients were markedly higher compared with those of healthy controls. Moreover, the serum TWEAK level was positively correlated with the serum IP and serum MCP-1 levels (p < 0.001 for both). The serum TWEAK levels, SLEDAI scores, and urine protein/creatinine levels were significantly different between the SLE group with non-renal involvement and with renal involvement (p = 0.034, p < 0.001, and p < 0.001, respectively). The serum TWEAK level was a crucial determinant for a high SLEDAI score and renal involvement (p = 0.044 and p = 0.046, respectively).
conclusionSerum TWEAK might be a serologic biomarker candidate that reflects disease activity and renal involvement in patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.